Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

70.29
+1.331.93%
Volume:108.30K
Turnover:7.57M
Market Cap:2.97B
PE:-30.39
High:70.84
Open:68.72
Low:68.70
Close:68.96
52wk High:76.81
52wk Low:38.51
Shares:42.21M
Float Shares:30.35M
Volume Ratio:0.70
T/O Rate:0.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3129
EPS(LYR):-3.0729
ROE:-31.46%
ROA:-14.06%
PB:8.92
PE(LYR):-22.87

Loading ...

Tarsus Pharmaceuticals Q2 EPS $(0.48) Misses $(0.39) Estimate, Sales $102.660M Beat $95.682M Estimate

Benzinga
·
Aug 07

BRIEF-Tarsus Pharmaceuticals Q2 EPS USD -0.48

Reuters
·
Aug 07

Tarsus Pharmaceuticals: European Regulatory Approval for a Preservative-Free Formulation of Xdemvy Is Expected in 2027

THOMSON REUTERS
·
Aug 07

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

GlobeNewswire
·
Aug 07

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

GlobeNewswire
·
Jul 31

Jeffrey Farrow, Officer, Reports Disposal of Tarsus Pharmaceuticals Inc. Common Shares

Reuters
·
Jun 19

Tarsus Pharmaceuticals Inc. Concluded Annual Stockholders Meeting

Reuters
·
Jun 19

Chief Medical Officer Elizabeth Yeu Reports Disposal of Common Shares in Tarsus Pharmaceuticals Inc

Reuters
·
Jun 18

Aziz Mottiwala, Chief Commercial Officer, Reports Disposal of Tarsus Pharmaceuticals Common Shares

Reuters
·
Jun 12

Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating

MT Newswires Live
·
Jun 02

Tarsus Pharmaceuticals Inc. to Participate in Upcoming William Blair 45th Annual Growth Stock Conference

Reuters
·
May 30

Tarsus Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
May 27

Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
May 05

Press Release: Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

Dow Jones
·
May 05

Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
May 03

Stock Track | Tarsus Pharmaceuticals (TARS) Plunges 7.95% Pre-Market Despite Beating Q1 Earnings Estimates

Stock Track
·
May 02

Tarsus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 02